Mechanisms for Activation of Beige Adipose Tissue in Humans

• Status: Recruiting
• Trial end date: 2024-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Mirabegron (Myrbetriq®, Astellas) is a highly specific and well-tolerated ß3 agonist marketed for overactive bladder. This trial will assess the effects of mirabegron on glucose tolerance and adipose tissue in prediabetic patients

• Phase: Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Philip Kern
• Treatments: Mirabegron

Criteria

Inclusion Criteria:

• BMI 27-45

• prediabetes (A1c 5.7-6.4)

• impaired fasting glucose or impaired glucose tolerance

Exclusion Criteria:

• diabetes

• chronic use of anti-diabetic medication

• acute or chronic inflammatory condition

• unstable medical condition

• cancer

• renal insufficiency

• any contraindication for Mirabegron

• BMI >45